Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)

NCT ID: NCT02241057

Last Updated: 2017-03-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label study. A total of approximately 60 subjects will be randomly assigned to receive either the heat patch (30 subjects) with a temperature probe/skin reference probe or a heat patch (30 subjects) alone. The study will consist of 2 visits.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Temperature

Evaluate the temperature profile of the air activated 3-cell patch during 8 hours of wear

Group Type EXPERIMENTAL

Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)

Intervention Type DEVICE

Temperature Probe

Intervention Type OTHER

Adhesion

Evaluate the adhesion with and without the presence of a temperature probe

Group Type EXPERIMENTAL

Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)

Intervention Type DEVICE

Temperature Probe

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who complete an appropriately administered informed consent process that includes signing the consent form.
* Subjects 18-75 years old of either sex.
* Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
* Subjects who are in good general health.
* Subjects who are willing and able to have the test products applied as directed, and comply with study instructions.
* Participants must be willing to restrict their activity for the 8 hour patch wear time.
* All participants agree to wear a t-shirt provided by the site for the entire 8 hour patch wear time.

Exclusion Criteria

* Subjects who have a history of sensitivity to any of the test products or adhesion material.
* Subjects who are pregnant.
* Subject with excessive hair at the application sites, scar tissue, tattoo, or coloration that would interfere with placement of test product or skin assessment.
* Subjects with diabetes, rheumatoid arthritis, poor circulation or have any clinically significant chronic illness.
* Subjects with active dermatitis (including sunburn) in the treatment area, or other visible dermatological disease which, in the investigator's opinion, might interfere with the response to the test products or interfere with the skin assessments associated with the test products.
* Have history of significant dermatologic cancers (eg, melanoma, squamous cell carcinoma).
* Subjects who have used topical dermatological products in the application area within 24 hours prior to the test product application.
* Subject using a concomitant medication that, in the investigator's opinion, could interfere with the interpretation of study results. Examples of such drugs include non-steroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin), topical or systemic corticosteroids, and cold/cough products containing antihistamines and/or either phentolamine, pseudoephedrine or phenylpropanolamine.
* Subjects who have received an investigational medication or device within 30 days prior to enrolment into this study.
* Subjects who are currently participating in an investigational study.
* Subject who are known to be noncompliant or are unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chattem, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ellen Bonagua, MD

Role: PRINCIPAL_INVESTIGATOR

Chattem, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wilkins Research

Chattanooga, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014011

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Leg Heat Therapy in Elderly Individuals
NCT05543980 COMPLETED PHASE1